Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-155-5p mimic
- Development stage
- Preclinical
- Lead developer
- MedChemExpress
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intraperitoneal, Intravenous
01
Overview
miR-155-5p mimic is a synthetic, double-stranded RNA oligonucleotide designed to emulate the function of the endogenous human microRNA miR-155-5p. By upregulating miR-155-5p activity, it modulates various signaling pathways, including HIF1α, Smad2/3, and NF-κB. While miR-155-5p often acts as an oncomiR in cancers such as clear cell renal cell carcinoma (ccRCC) and non-small cell lung cancer (NSCLC), its mimic is primarily used as a research tool to study gene regulation and potential therapeutic applications in inflammatory conditions like acute respiratory distress syndrome (ARDS). It is currently available only as a research-grade reagent and has not entered clinical development.
- Other names
- hsa-miR-155-5p mimichsa-miR155-5p mimichsa-miR 155-5p mimicmicroRNA-155-5p mimicmicroRNA155-5p mimicmicroRNA 155-5p mimic
02
Targets
FOXO3 (Forkhead box protein O3)PIK3R1 (Phosphatidylinositol 4-phosphate 3-kinase regulatory subunit alpha)Ras homolog family member A (mRNA)SMAD3 (SMAD family member 3)ZEB1 (Zinc finger E-box-binding homeobox 1)HIF1A (Hypoxia-inducible factor 1-alpha)SMAD2 (Mothers against decapentaplegic homolog 2)NF-κBRHOA (Ras homolog gene family member A)ZEB2 (Zinc finger E-box-binding homeobox 2)
Beyond the preview
Go deeper on miR-155-5p mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-155-5p mimic.